The stock of Adicet Bio, Inc. (ACET) skyrocketed today after the company announced positive interim clinical data on their first-ever allogeneic gamma delta CAR T investigational cell therapy related to cancer and other diseases.
The stock gained more than 32.24% to reach $12.96 at the time of this writing. At the end of the last trading session, the stock closed at $10.35. The average volume of the stock traded in the trading session was approx. 144.06K in total.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Reason for the ACET stock significant gain:
Adicet Bio, Inc. (ACET), a biotechnology company discovered and developed their first in class allogeneic gamma delta CAR T cell therapies. The therapies are related to cancer and other diseases. Today the company announced positive interim data from their dose-escalation Phase 1 trial evaluating the safety and dependability of ADI-001. The investigational therapy is supposed to target the CD20 which could be major breakthrough in the potential treatment of B-cell Non-Hodgkin’s Lymphoma in the patients.
In data that is obtained from 6 patients that participated in the study as of 22 Nov 2021 the responses were observed with ADI-001that start giving promising results at the lowest level of dose in stage 1 study for the treatment of B-cell Non-Hodgkin’s Lymphoma.
No serious adverse events were found related to ADI-001 that also includes GvHD, neurotoxicity or high-grade CRS have been reported to date.
Expansion and circulating evidence of Vivo in pharmacodynamic biomarkers were observed to be consistent with ADI-001 activation.
The safety and clinical activity which shows promising results assures the potential of Adicet Bio, Inc., a first-in-class allogeneic gamma delta CAR T cell platform.
The profound and early complete responses in Phase 1 dose-finding study evaluate the ADI-001 as monotherapy among patients with very advanced cancer starting at their first dose level of 30 million CAR+ cells. Data available as of now suggests that ADI-001 is highly clinically active.
Effects on the stocks:
This is a major development for the company and good news for the investors who have already invested in its stock. This development has motivated me to take a serious interest in the stock of Adicet Bio, Inc. (ACET). With this remarkable and profound discovery in the treatment of cancer and other diseases, the company is set to serve and treat the patients with more promising results. This will have a significant effect on the profitability of the company and the rise of the stock.
The company is looking forward to reporting additional data related to the study in the 1sthalf of 2022. They are rapidly progressing their performance to gain fruitful results to the full potential of their gamma delta CAR T cell platform for cancer and other diseases patients.